1-2 of 2
Mathew Streetly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Rakesh Popat, MD PhD, Ruth Mary De Tute, BSc,MSc, Nicholas Counsell, Dunnya De-Silva, Beth Phillips, MBBS, FRCPath, BSc, James D Cavenagh, Toyin Adedayo, Nivette Braganza, Claire Roddie, PhD MD, Mathew Streetly, Stephen Schey, MBBS, Mickey Koh, MD PhD, Josephine Crowe, Michael F. Quinn, FRCPath, MB, MD MRCP, Shirley D'Sa, MD FRCP, FRCPath, Andres E. Virchis, FRCP, FRCPath, Gordon Cook, PhD, Charles R Crawley, Guy Pratt, MD FRCP, FRCPath, Mark Cook, MBChB,PhD, Paul Smith, Laura Clifton-Hadley, PhDBSc, Neil Rabin, Roger G Owen, MD, Kwee Yong, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1864.
https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864
Published: 2017
Journal Articles

The Thalidomide Analogue (Actimid) Induces T-Cell Activation at Day 28 in Patients with Relapsed Refractory Myeloma but Does Not Correlate with Improved Outcome.

Gulrukh Ahsan, MSc, Mathew Streetly, MD, Paul A. Fields, MD, PhD, Auther R. Bradwell, PhD, Steve A. Schey, MD, Majid Kazmi, MD
Journal: Blood
Blood (2005) 106 (11): 3473.
https://doi.org/10.1182/blood.V106.11.3473.3473
Published: 2005